HIGHBuilt-in & outside partyPipeline
RPx platform
“10-K Item 1A: 'all of the product candidates in our current pipeline are based on our proprietary RPx platform ... we may be required to discontinue development of all product candidates'”
REPL · Concentration risk · 10-K extracted
Replimune Group (REPL) concentration risks
Updated
The most significant concentration Replimune Group discloses is RPx platform, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Replimune Group’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 2 disclosed concentrations
HIGH2
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
HIGHOutside partySupplier
BMS nivolumab supply
“10-K Item 1A: 'We have entered into agreements with BMS for the supply of nivolumab, its anti-PD-1 therapy, for use in connection with our ongoing IGNYTE Phase 1/2 trials with RP1'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-07-06Replimune's concentration risk is twofold and compounding. First, all of the product candidates in its current pipeline are based on its proprietary RPx platform, and the company discloses that if the platform approach proves unsuccessful, it may be required to discontinue development of all product candidates — a high-share, platform-wide dependency that is structural to how the entire pipeline is built, meaning a single technological setback could affect every program at once rather than just one. Second, Replimune has entered into agreements with BMS for the supply of nivolumab, its anti-PD-1 therapy, for use in its ongoing IGNYTE Phase 1/2 trials with RP1 — a supplier dependency on a single external partner for a component therapy used in a key clinical program. Neither exposure carries a disclosed percentage, but both are characterized as high-share reliance: on the platform underpinning the whole pipeline, and on a single supplier for a critical trial component. Together, these exposures mean Replimune's near-term trajectory depends heavily both on the scientific validity of one core technology and on the continuity of one external supply relationship, with limited diversification across either dimension.
For the engine’s reasoning on REPL’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Biotechnology
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| REPL● | Replimune Group, Inc. | 2 | 0 | 0 | 2 |
| ABUS | Arbutus Biopharma Corporation | 1 | 1 | 0 | 2 |
| ABSI | Absci Corporation | 1 | 0 | 0 | 1 |
| ABCL | AbCellera Biologics Inc. | 0 | 0 | 0 | 0 |
| ACHV | Achieve Life Sciences, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.